v3.20.4
Product, Geographic and Other Revenue Information (Tables)
 12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Areas
The following summarizes revenues by geographic area:
 Year Ended December 31,
(MILLIONS OF DOLLARS)202020192018
United States$21,712 $20,593 $20,119 
Developed Europe7,788 7,729 7,997 
Developed Rest of World4,036 4,022 4,090 
Emerging Markets8,372 8,828 8,618 
Revenues
$41,908 $41,172 $40,825 
Schedules of Concentration of Risk
The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers:
 Year Ended December 31,
202020192018
McKesson, Inc.
16 %15 %13 %
AmerisourceBergen Corporation
13 %11 %8 %
Cardinal Health, Inc.10 %9 %8 %
Schedule of Significant Product Revenues
The following provides detailed revenue information for several of our major products:
(MILLIONS OF DOLLARS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202020192018
TOTAL REVENUES(a)
$41,908 $41,172 $40,825 
Internal Medicine(a)
$9,003 $8,790 $8,548 
Eliquis alliance revenues and direct sales
Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism4,949 4,220 3,434 
Chantix/Champix
An aid to smoking cessation treatment in adults 18 years of age or older
919 1,107 1,085 
Premarin family
Symptoms of menopause680 734 832 
BMP2
Development of bone and cartilage274 287 279 
Toviaz
Overactive bladder252 250 271 
All other Internal Medicine
Various1,930 2,192 2,648 
Oncology$10,867 $9,014 $7,471 
IbranceMetastatic breast cancer5,392 4,961 4,118 
Xtandi alliance revenuesmCRPC, nmCRPC, mCSPC1,024 838 699 
Sutent
Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor
819 936 1,049 
Inlyta
Advanced RCC787 477 298 
Xalkori
ALK-positive and ROS1-positive advanced NSCLC544 530 524 
Bosulif
Philadelphia chromosome–positive chronic myelogenous leukemia450 365 296 
Retacrit(b)
Anemia386 225 82 
Lorbrena
ALK-positive metastatic NSCLC
204 115 11 
Ruxience(b)
Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis170 (1)— 
Braftovi
In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy
160 48 — 
Zirabev(b)
Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer143 1 — 
Mektovi
In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation142 49 — 
All other Oncology
Various645 470 395 
Hospital(a), (c)
$7,961 $7,772 $7,955 
Sulperazon
Bacterial infections618 684 613 
MedrolAnti-inflammatory glucocorticoid402 469 493 
EpiPen(a)
Epinephrine injection used in treatment of life-threatening allergic reactions297 303 303 
ZithromaxBacterial infections276 336 326 
Vfend
Fungal infections270 346 392 
PanzygaPrimary humoral immunodeficiency269 183 39 
PrecedexSedation agent in surgery or intensive care260 155 213 
Fragmin
Treatment/prevention of venous thromboembolism252 253 293 
Zyvox
Bacterial infections222 251 236 
ZaviceftaBacterial infections212 108 46 
Pfizer CentreOne(d)
Various926 810 755 
All other Anti-infectives
Various1,455 1,592 1,661 
(MILLIONS OF DOLLARS)Year Ended December 31,
PRODUCTPRIMARY INDICATION OR CLASS202020192018
All other Hospital(c)
Various2,502 2,281 2,584 
Vaccines
$6,575 $6,504 $6,332 
Prevnar 13/Prevenar 13
Pneumococcal disease5,850 5,847 5,802 
Nimenrix
Meningococcal disease221 230 140 
FSME/IMMUN-TicoVac
Tick-borne encephalitis disease
196 220 184 
BNT162b2
Active immunization to prevent COVID-19 in individuals 16 years of age and older
154 — — 
All other Vaccines
Various154 207 206 
Inflammation & Immunology (I&I)$4,567 $4,733 $4,720 
Xeljanz
RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis2,437 2,242 1,774 
Enbrel (Outside the U.S. and Canada)
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
1,350 1,699 2,112 
Inflectra/Remsima(b)
Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis
659 625 642 
All other I&I
Various121 167 192 
Rare Disease
$2,936 $2,278 $2,211 
Vyndaqel/VyndamaxATTR-cardiomyopathy and polyneuropathy1,288 473 148 
BeneFIXHemophilia B454 488 554 
Genotropin
Replacement of human growth hormone427 498 558 
Refacto AF/Xyntha
Hemophilia A370 426 514 
Somavert
Acromegaly277 264 267 
All other Rare Disease
Various120 129 170 
Consumer Healthcare Business(e)
$— $2,082 $3,587 
Total Alliance revenues$5,418 $4,648 $3,838 
Total Biosimilars(b)
$1,527 $911 $769 
Total Sterile Injectable Pharmaceuticals(a). (f)
$5,315 $5,013 $5,173 
(a)On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan) and we transferred the operations that were part of the Mylan-Japan collaboration to Viatris. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and the Mylan-Japan collaboration are reported as Income from discontinued operations––net of tax for all periods presented. Prior-period financial information has been restated, as appropriate. Prior to the separation of the Upjohn Business, and beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and the Mylan-Japan collaboration. As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan were reported in Upjohn beginning in the first quarter of 2020. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary are reported in the Hospital therapeutic area for all periods presented in our consolidated financial statements.
(b)Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev.
(c)Hospital is a therapeutic area that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne(d). All other Hospital primarily includes revenues from legacy Sterile Injectable Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
(d)Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
(e)On July 31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare JV. See Note 2C.
(f)Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.